Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Update on botulinum toxin and pain (CROSBI ID 581299)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Matak, Ivica ; Bach-Rojecky, Lidija ; Filipovic, Boris ; Gagula, Zeljka ; Durovic, Nevena ; Stracenski, Ivana ; Lackovic, Zdravko Update on botulinum toxin and pain // Structural Plasticity & Reorganization in Chronic Pain - Program & Abstract book / Gupta, Pooja ; Kuner, Rohini (ur.). Heidelberg: Neumann Druck, 2011. str. 55-56

Podaci o odgovornosti

Matak, Ivica ; Bach-Rojecky, Lidija ; Filipovic, Boris ; Gagula, Zeljka ; Durovic, Nevena ; Stracenski, Ivana ; Lackovic, Zdravko

engleski

Update on botulinum toxin and pain

Only definitively known molecular target of botulinum toxin type A is SNAP-25, a protein involved in neurotransmitter vesicle release. Association of this effect with acetylcholine release in the neuromuscular junction is a textbook knowledge. However, in series of experiments we and other authors demonstrated that botulinum toxin reduces also inhibits pain perception, presumably inhibiting release of other neurotransmitters than acetylcholine. Up to now it is shown that botulinum toxin (BTX) does not reduce acute superficial nociceptive pain like thermal" (hot plate), "mechanical" pain (paw pressure test), but it reduces longer acting chemical pain like carageenan, capsaicin and second phase of formalin-induced pain. Up to now its action on visceral pain is shown only in capsaicin-induced prostate pain. The effect on deep somatic pain was investigated in formalin-induced knee joint pain. BTX reduces also a neuropathic pain induced by nerve ligature, diabetes or cytostatic paclitaxel. In comparison to several classical analgesics, BTX reduced only second phase of pain induced by subcutaneous injection of formalin. Potentially the greatest benefit of BTX might be its long lasting effect. Opposite of a different report we found that BTX is effective even after multiple applications. In several pain models we demonstrated that antinociceptive effect of peripherally applied BTX is axonal transport dependent. After BTX peripheral injection recently we found immunohistochemical evidence of enzymatic activity of BTX in central sensory areas. Our additional experiments completely excluded the possibility that peripheral sensory nerve endings contribute to antinociceptive effect of BTX. Discovery that BTX action on pain is exclusively a central effect rises many new questions: is it associated only with some neurotransmitters, or only with some types of nerves, or only with some types of ion channels? Is BTX associated with central synaptic remodeling like in neuromuscular junction? In conclusion we must admit that after these new discoveries we understand less than we previously (wrongly) believed. Supported by Croatian Ministry of Science, Education and Sport and Deutscher Academischer Austauch Dienst.

botulinum toxin type A; antinociceptive activity; sensory neurons; axonal transport

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

55-56.

2011.

objavljeno

Podaci o matičnoj publikaciji

Structural Plasticity & Reorganization in Chronic Pain - Program & Abstract book

Gupta, Pooja ; Kuner, Rohini

Heidelberg: Neumann Druck

Podaci o skupu

Structural Plasticity & Reorganization in Chronic Pain

poster

01.01.2011-01.01.2011

Heidelberg, Njemačka

Povezanost rada

nije evidentirano